Le Lézard
Classified in: Ebola virus, Health, Covid-19 virus
Subject: SVY

Global Markets for Vaccine Technologies, 2020-2025: Recent Outbreaks of Covid-19 & Zika Virus Account for Recent Market Growth


DUBLIN, Sept. 22, 2020 /PRNewswire/ -- The "Global Markets for Vaccine Technologies" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The market is mainly driven by the sales of major human vaccines such as Prevnar 13, Gardasil, ProQuad, Varivax, M-M-R II, polio/pertussis/Hib vaccines, and influenza vaccines.

There has been increasing government interest in various parts of the world due to sudden outbreaks of major diseases such as Ebola, Zika virus, chikungunya, avian influenza, the H1N1 virus, and COVID-19; these outbreaks have been the primary reason for the recent market growth.

Regulations are in place to check outbreaks due to tourists carrying the diseases, and vaccines have become a requirement in some countries and are highly recommended for international travelers. Various government programs and increased public awareness regarding viral diseases such as hepatitis, measles-mumps-rubella (MMR), and polio have augmented vaccination rates in various countries. The growth in this industry is also driven by the global population increases and the acceptance of adult vaccines.

Vaccines can significantly reduce the burden of many diseases and increase life expectancy through prevention. The introduction of newer vaccines covering many diseases is another factor pushing the market towards significant growth. New product offerings to address unmet needs, contingency planning for pandemic infections, awareness of disease prevention, improving economic conditions in developing countries, and increasing interest and investments from major pharmaceutical companies are shaping the vaccine market.

Growth in the vaccine market is anticipated on the basis of technological advancements with respect to the development of novel vaccines towards emerging infectious diseases, cancers, and allergies. Continuous improvements in vaccine design, delivery technologies, and manufacturing will also help market growth.

The global animal vaccine market is also growing in importance. Increasing demand for livestock products and an increase in pet ownership are the foremost reasons for increasing vaccination in animals. Significant developments in biotechnology, informatics, and information systems have prompted better planning and execution of animal disease prevention in many countries.

In terms of geography, North America accounted for a major share in the total vaccine market, along with Asia-Pacific. The North American market is driven by strict regulations and high awareness, whereas the Asia-Pacific market is driven by high demand due to the broad prevalence of diseases such as influenza and hepatitis.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Breakdown by Human Vaccine

Chapter 5 Market Breakdown by Animal Vaccine

Chapter 6 Market Breakdown by Region

Chapter 7 COVID-19 Impact on Present and Future

Chapter 8 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/ywonz8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...

24 avr 2024
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024. Highlights for the Quarter: Net income available to common...

24 avr 2024
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related...

24 avr 2024
Teradyne, Inc. reported revenue of $600 million for the first quarter of 2024 of which $412 million was in Semiconductor...

24 avr 2024
Alamos Gold Inc. ("Alamos" or the "Company") today reported its financial results for the quarter ended March 31, 2024. "We delivered another strong start to the year across a number of fronts, following a record performance in 2023. Costs...



News published on and distributed by: